ClinicalTrials.gg
TerminatedNCT06191796Updated Jun 12, 2025

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

A Phase 1 interventional study of zanzalintinib and AB521 in Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors, sponsored by Exelixis. Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated prior to starting the Phase 2 portion due to a business decision.

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing zanzalintinib in Carcinoma, Renal Cell — 10 open to participants now, 12 under way, 4 of them phase 3. zanzalintinib · Carcinoma, Renal Cell.

Enrollment
12th of 13
25 · median 140
Started
2024
the only one that year
Phase 1
3 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
5 of 13
Exelixis

Among the 13 studies testing zanzalintinib in Carcinoma, Renal Cell, this one is the 12th largest by enrollment, is the only one that started in 2024, is one of 3 in phase 1, and was the 4th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 13 studies testing zanzalintinib in Carcinoma, Renal Cell are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About zanzalintinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing zanzalintinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with AB521 (doublet) and in combination with AB521 plus nivolumab (triplet) in participants with advanced ccRCC or other advanced solid tumors. The main questions it aims to answer are:

  • The recommended doses (RDs)
  • The safety and tolerability
  • The PK and the preliminary efficacy
03

Conditions studied

  • Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants with a).unresectable advanced or solid tumor; b). unresectable advanced or metastatic clear cell renal cell carcinoma and no prior anticancer therapy; or c). unresectable advanced or metastatic clear cell renal cell carcinoma and has received at least one prior anticancer therapy.
  2. according to version 1.1 (RECIST 1.1; Eisenhauer et al, 2009) as determined by the Investigator.
  3. For all participants, material should be obtained; if archival tissue is not available or is older than 2 years, then a fresh biopsy should be obtained, if medically feasible. Specific requirements for tumor tissue samples will be described in the Laboratory Manual.
  4. Recovery to baseline or ≤ Grade 1 per (CTCAE) v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.
  5. Performance Status (KPS) ≥70%.
  6. Screening ambulatory oxygen saturation (SpO2) ≥92%.
  7. Screening (LVEF) above the institutional lower limit of normal.

Key Exclusion Criteria:

  1. Participants who have been previously treated with a HIF-2α targeted therapy and/or zanzalintinib.
  2. Radiation therapy for bone metastases within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Participants with clinically-relevant ongoing complications from prior radiation therapy are not eligible.
  3. Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
  4. Concomitant anticoagulation with oral anticoagulants except for a). prophylactic use of low-dose aspirin for cardioprotection or low dose low molecular weight heparins (LMWH) or b). therapeutic doses of LMWH or specified direct factor Xa inhibitors.
  5. Administration of a live, attenuated vaccine within 30 days prior to enrollment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Dose-finding Cohort A: Zanzalintinib + AB521

    Participants with solid tumors will receive zanzalintinib + AB521

    Drug: zanzalintinib · Drug: AB521

  • Experimental
    Dose-finding Cohort B: zanzalintinib + AB521 + nivolumab

    Participants with ccRCC will receive zanzalintinib + AB521 + nivolumab

    Drug: zanzalintinib · Drug: AB521 · Biological: Nivolumab

  • Experimental
    Expansion Cohort 1: Zanzalintinib + AB521

    Participants with ccRCC will receive zanzalintinib + AB521

    Drug: zanzalintinib · Drug: AB521

  • Experimental
    Expansion Cohort 2: zanzalintinib + AB521 + nivolumab

    Participants with ccRCC will receive zanzalintinib + AB521 + nivolumab

    Drug: zanzalintinib · Drug: AB521 · Biological: Nivolumab

Interventions

  • Specified doses on specified days

    Also known as: XL092

  • DrugAB521

    Specified doses on specified days

  • BiologicalNivolumab

    Specified doses on specified days

    Also known as: OPDIVO®

06

What researchers measure

Primary outcomes

  1. Dose-finding Stage: Number of participants with dose-limiting toxicities (DLTs)

    Time frame: Up to 24 months

  2. Expansion Stage: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the Investigator

    Time frame: Up to 24 months

Secondary outcomes

  1. Dose-finding Stage: Number of participants with adverse events (AEs), including serious adverse events (SAEs) and immune-mediated adverse events (imAEs)

    Time frame: Up to 24 months

  2. Dose-finding Stage: Concentration of study treatments (zanzalintinib and AB521) in plasma at specified time points

    Time frame: Up to 24 months

  3. Dose-finding Stage: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the Investigator

    Time frame: Up to 24 months

  4. Expansion Stage: Number of participants with adverse events (AEs), including serious adverse events (SAEs), and immune-mediated adverse events (imAEs)

    Time frame: Up to 24 months

  5. Expansion Stage: Duration of response (DOR) per RECIST 1.1 as assessed by the Investigator

    Time frame: Up to 24 months

  6. Expansion Stage: Progression-free survival (PFS) per RECIST 1.1 as assessed by the Investigator

    Time frame: Up to 24 months

  7. Expansion Stage: Overall survival (OS)

    Time frame: Up to 24 months

  8. Expansion Stage: Concentration of study treatments (zanzalintinib and AB521) in plasma at specified time points

    Time frame: Up to 24 months

07

Study locations

14 sites
  • Exelixis Site #8
    Los Angeles, California 90033, United States
  • Exelixis Site #9
    Miami, Florida 33176, United States
  • Exelixis Clinical Site #1
    Orlando, Florida 32804, United States
  • Exelixis Site #11
    Tampa, Florida 33612, United States
  • Exelixis Site #6
    Scarborough, Maine 04074, United States
  • Exelixis Site #5
    Saint Louis, Missouri 63110, United States
  • Exelixis Site #15
    Bronx, New York 10469, United States
  • Exelixis Clinical Site #3
    New Hyde Park, New York 11776, United States
  • Exelixis Site #14
    New York, New York 10028, United States
  • Exelixis Site #13
    Shirley, New York 11987, United States
  • Exelixis Clinical Site #2
    Nashville, Tennessee 37203, United States
  • Exelixis Clinical Site #16
    Salt Lake City, Utah 84112, United States
  • Exelixis Site #4
    Spokane, Washington 99208, United States
  • Exelixis Site #12
    Madison, Wisconsin 53792, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in May 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 5, 2024
StartActual
Jan 25, 2024
Primary completionActual
May 12, 2025
CompletionActual
May 12, 2025
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06191796
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Jan 25, 2024
Primary completion
May 12, 2025
Completion
May 12, 2025
Last update
Jun 12, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zanzalintinib · Casdatifan

Start the discussion